Company ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per region

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed London S.E. Other stock markets 01:08:17 27/06/2024 pm IST			5-day change	1st Jan Change
2.053 ^GBX	-4.28%		-8.33%	+23.17%

05/06	ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/04	Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	CI

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Number of employees: 5

Managers	Title	Age	Since
Tim McCarthy McCarthy CEO	Chief Executive Officer	68	30/15/30
Timothy Franklin COO	Chief Operating Officer	60	01/20/01
Lisa Baderoon BRD	Director/Board Member	57	29/12/29

Members of the board	Title	Age	Since
Tim McCarthy McCarthy CEO	Chief Executive Officer	68	30/15/30
Timothy Franklin COO	Chief Operating Officer	60	01/20/01
Lisa Baderoon BRD	Director/Board Member	57	29/12/29
Laurence Reilly BRD	Director/Board Member	42	11/23/11
Sebastien Goudreau CTO	Chief Tech/Sci/R&D Officer	-	11/23/11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	416,437,265	237,368,751 ( 57.00 %)	0	57.00 %

Name	Equities	%	Valuation
KW Investment Management Ltd. 13.38 %	55,706,000	13.38 %	2 M p
Lanstead Capital Investors LP 12.99 %	54,111,858	12.99 %	1 M p
Hargreaves Lansdown Asset Management Ltd. 5.586 %	23,261,000	5.586 %	635 258 p
Chelverton Asset Management Ltd. 3.602 %	15,000,000	3.602 %	409 650 p
HSBC Global Asset Management (UK) Ltd. 3.216 %	13,393,000	3.216 %	365 763 p
IG Markets Ltd. 2.884 %	12,009,000	2.884 %	327 966 p
Bank J. Safra Sarasin AG (Investment Management) 0.7794 %	3,245,686	0.7794 %	88 640 p
Clearstream Banking SA 0.6729 %	2,802,000	0.6729 %	76 523 p
Jarvis Investment Management Ltd. 0.5742 %	2,391,000	0.5742 %	65 298 p
HSBC Bank Plc (Market-Maker) 0.5650 %	2,353,000	0.5650 %	64 260 p

ImmuPharma Plc

One Bartholomew Close

EC1A 7BL, London

+44 20 7206 2650

http://www.immupharma.com

Name	Category and Sector
IMMUPHARMA PLC	Pharmaceuticals: Other

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUPHARMA PLC	+23.17%	1.13Cr
MODERNA, INC.	+23.13%	4.69TCr
LONZA GROUP AG	+37.29%	3.91TCr
IQVIA HOLDINGS INC.	-8.73%	3.85TCr
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	3.1TCr
CELLTRION, INC.	-12.26%	2.61TCr
ICON PUBLIC LIMITED COMPANY	+10.57%	2.59TCr
UNITED THERAPEUTICS CORPORATION	+45.05%	1.42TCr
MEDPACE HOLDINGS, INC.	+32.23%	1.25TCr
BIO-TECHNE CORPORATION	-6.56%	1.14TCr

Other Biotechnology & Medical Research